pn 881 peptide Updated Edition,PN-881

The landscape of treating immune-mediated skin diseases, particularly psoriasis, is evolving with the emergence of novel therapeutic agents. Among these, the PN-881 peptide stands out as a first-in-class oral peptide antagonist of interleukin-17 (IL-17). Developed by Protagonist Therapeutics, PN-881 represents a significant advancement in targeted therapies, offering a potentially more convenient and effective treatment option for patients.

The PN-881 peptide is designed to inhibit the IL-17 pathway, a critical driver of inflammation in various immune-mediated conditions. Research has demonstrated that PN-881 inhibits IL-17-induced IL-6 production in human cells, underscoring its mechanism of action. This oral interleukin-17 peptide antagonist is being developed for immune-mediated skin diseases, with a particular focus on psoriasis. Preclinical data presented on PN-881, the next generation IL-17 oral peptide antagonist for psoriasis, have shown promising results, including effective blockade in vivo of IL-17 in serum and skin.

PN-881 is characterized as an orally delivered macrocyclic peptide that potently and selectively binds to IL-17A and IL-17F. This selective binding allows it to block the three dimeric forms of the cytokine, offering a comprehensive approach to targeting IL-17 driven inflammation. The PN-881 peptide has demonstrated high binding affinity to IL-17A and IL-17F, with nanomolar to picomolar in vitro potency. This potent activity, combined with its oral bioavailability, positions PN-881 as a potential best-in-class oral peptide.

The development candidate, PN-881, has been identified as a crucial step forward by Protagonist Therapeutics. The company has announced the nomination of PN-881, a potential best-in-class oral peptide, highlighting its promising therapeutic profile. Further supporting its potential, PN-881 has the potential to be the first-in-class oral peptide targeting all three IL-17 isoforms, which are considered the main drivers of skin inflammation.

In preclinical studies, oral PN-881 significantly reduced IL-23-induced ear inflammation at low doses, showcasing its efficacy in reducing inflammatory responses. The drug's pharmacokinetic profile is also noteworthy, with demonstrated stability in simulated gastric and intestinal fluids, as well as in serum with a half-life greater than 24 hours. This metabolic stability is crucial for an oral therapeutic.

The significance of PN-881 is further amplified by its classification as a first-in-class oral peptide targeting the IL-17 pathway. Its development is a testament to the ongoing innovation in the field of targeted therapies. While not yet approved, PN-881: a IL-17 inhibitors Drug is currently in Phase 1 clinical trials, with Protagonist Therapeutics preparing it for Phase 1 testing in late 2025. This marks a significant milestone, moving from preclinical characterization to human studies.

The broader context of oral therapies for inflammatory diseases is also worth noting. While the focus here is on PN-881, the success of other oral peptides, such as the oral IL-23-blocking peptide that has achieved phase III wins in inflammatory disease, suggests a growing trend towards oral administration for such conditions. The recent FDA approval of ICOTYDE™ (icotrokinra), a targeted oral peptide for the first-line systemic treatment of plaque psoriasis, further validates the potential of this drug class. PN-881 represents Protagonist's next generation of oral peptides for psoriasis, building on the company's expertise in this area.

The PN-881 molecule is a subject of ongoing research and presentation at scientific conferences. Preclinical data on PN-881, a first-in-class oral peptide targeting the IL-17 pathway, have been presented at events like the Society for Investigative Dermatology. These presentations often detail the drug's potent and selective binding to IL-17A and -17F, and its ability to block the cytokine effectively, with demonstrated nanomolar to picomolar in vitro potency. The identification of PN-881 as a development candidate by Protagonist Therapeutics signifies a commitment to advancing this promising therapy.

In summary, the PN-881 peptide is a novel, orally administered macrocyclic peptide antagonist of IL-17. Its ability to potently and selectively inhibit IL-17, coupled with its favorable pharmacokinetic properties and its designation as a first-in-class oral therapy, positions it as a significant contender in the treatment of immune-mediated skin diseases, particularly psoriasis. As clinical trials progress, the PN-881 holds the promise of offering a more convenient and effective therapeutic option for patients.